Decipher the Helicobacter pylori Protein Targeting in the Nucleus of Host Cell and their Implications in Gallbladder Cancer: An <i>insilico</i> approach

Wang, Yunjian; Alam, Imran; Shami, Ashwag; Chaudhary, Anis Ahmad; Khan, Shahanavaj

doi:10.7150/jca.63517

Cited by 16 publications

(8 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, novel immunotherapy strategies are urgently needed for the majority of patients with mCRC. With the advancement of molecular techniques, next‐generation sequencing (NGS) analyses focused on novel approaches for the characterization and identification of microbial communities, which play an important role in different diseases and cancers such as colon cancer, cervical cancer, prostate cancer, lung cancer and gallbladder cancer 5‐10 …”

Section: Introductionmentioning

confidence: 99%

“…With the advancement of molecular techniques, nextgeneration sequencing (NGS) analyses focused on novel approaches for the characterization and identification of microbial communities, which play an important role in different diseases and cancers such as colon cancer, cervical cancer, prostate cancer, lung cancer and gallbladder cancer. [5][6][7][8][9][10] We have recently reported the results of Cetuximab-AVElumab-mCRC (CAVE-mCRC), a single-arm, phase II trial, in which the combination of cetuximab, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) plus avelumab, an antiprogrammed death ligand 1 (PD-L1) mAb, was evaluated as rechallenge strategy in chemo-refractory RAS wild type (WT) mCRC patients. 11 The rationale for this combination is based on the induction of antibody-dependent cell-mediated cytotoxicity (ADCC) by these two IgG isotype mAbs, which could enhance Natural Killer (NK) cell-mediated antitumor immune response.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab

Martini

Ciardiello

Dallio

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Gut microbiota is involved in immune modulation and immune checkpoint inhibitors (ICIs) efficacy. Single-arm phase II CAVE-mCRC and CAVE-LUNG clinical trials investigated cetuximab + avelumab combination in RAS wild-type (WT) metastatic colorectal cancer (mCRC) and chemo-refractory nonsmall cell lung cancer (NSCLC) patients, respectively. A comprehensive gut microbiota genetic analysis was done in basal fecal samples of 14 patients from CAVE-mCRC trial with circulating tumor DNA (ctDNA) RAS/BRAF WT and microsatellite stable (MSS) disease. Results were validated in a cohort of 10 patients from CAVE-Lung trial. 16S rRNA sequencing revealed 23 027 bacteria species in basal fecal samples of 14 patients from CAVE-mCRC trial. In five long-term responding patients (progression-free survival [PFS],9-24 months) significant increases in two butyrate-producing bacteria, Agathobacter M104/1 (P = .018) and Blautia SR1/5 (P = .023) were found compared to nine patients with shorter PFS (2-6 months). A significantly better PFS was also observed according to the presence or absence of these species in basal fecal samples. For Agathobacter M104/1, median PFS (mPFS) was 13.5 months (95% confidence interval [CI], 6.5-20.5 months) vs 4.6 months (95% CI, 1.8-7.4 months); P = .006. For Blautia SR1/5, mPFS was 5.9 months (95% CI, 2.2-9.7 months) vs 3.6 months (95% CI, 3.3-4.0 months); P = .

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab

Martini

Ciardiello

Dallio

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…H. pylori can inhibit the expression of p53 protein and normal cellular transformation by expressing multiple effectors targeting the host nucleus, which in turn leads to GBC progression ( Arana and Kunkel, 2010 ; Wei et al., 2010 ). Its effectors include DNA topoisomerase, DNA polymerase III, bacterial insertion sequence 200 or 607 (IS200 or IS607), translation initiation factor-3 (IF-3), ribosome-recycling factor (RRF), 30S ribosomal protein S8 and various uncharacterized proteins ( Wang et al., 2021b ). DNA topoisomerase, DNA polymerase III, IS200 and IS607 cause genomic instability in infected cells by interfering with the process of gene replication ( Bao and Jurka, 2013 ; Subramaniam et al., 2014 ).…”

Section: Bacteria In Gbc Pathogenesismentioning

confidence: 99%

“…DNA topoisomerase, DNA polymerase III, IS200 and IS607 cause genomic instability in infected cells by interfering with the process of gene replication ( Bao and Jurka, 2013 ; Subramaniam et al., 2014 ). Among them, IS200 and IS607 encode a transposase (TnpA) and a protein (TnpB), respectively, thought to be methyltransferases ( Wang et al., 2021b ). Conversely, IF-3, RRF and 30S ribosomal protein S8 can disrupt protein synthesis by altering the transcription and translation processes of genes.…”

Section: Bacteria In Gbc Pathogenesismentioning

confidence: 99%

The footprint of gut microbiota in gallbladder cancer: a mechanistic review

Liu,

Li,

Chen

et al. 2024

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Gallbladder cancer (GBC) is the most common malignant tumor of the biliary system with the worst prognosis. Even after radical surgery, the majority of patients with GBC have difficulty achieving a clinical cure. The risk of tumor recurrence remains more than 65%, and the overall 5-year survival rate is less than 5%. The gut microbiota refers to a variety of microorganisms living in the human intestine, including bacteria, viruses and fungi, which profoundly affect the host state of general health, disease and even cancer. Over the past few decades, substantial evidence has supported that gut microbiota plays a critical role in promoting the progression of GBC. In this review, we summarize the functions, molecular mechanisms and recent advances of the intestinal microbiota in GBC. We focus on the driving role of bacteria in pivotal pathways, such as virulence factors, metabolites derived from intestinal bacteria, chronic inflammatory responses and ecological niche remodeling. Additionally, we emphasize the high level of correlation between viruses and fungi, especially EBV and Candida spp., with GBC. In general, this review not only provides a solid theoretical basis for the close relationship between gut microbiota and GBC but also highlights more potential research directions for further research in the future.

show abstract

“…A recent study by Wang et al [60] identified H. pylori proteins with potential involvement in gallbladder cancer pathogenesis using a bioinformatics approach. Briefly, the UniProt database containing the entire H. pylori proteome was used to predict which H. pylori proteins may potentially target the nucleus of host cells.…”

Section: Biliary Tract Cancersmentioning

confidence: 99%

The link between Helicobacter pylori infection and gallbladder and biliary tract diseases: A review

Lim

Lee

Jiang

et al. 2023

Ann Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

Helicobacter pylori is a gram-negative pathogen commonly associated with peptic ulcer disease and gastric cancer. H. pylori infection has also been reported in cholelithiasis, cholecystitis, gallbladder polyps, and biliary tract cancers. However, the association between H. pylori and gallbladder and biliary tract pathologies remains unclear due to the paucity of literature. In response to the current literature gap, we aim to review and provide an updated summary of the association between H. pylori with gallbladder and biliary tract diseases and its impact on their clinical management. Relevant peer-reviewed studies were retrieved from Medline, PubMed, Embase, and Cochrane databases. We found that H. pylori infection was associated with cholelithiasis, chronic cholecystitis, biliary tract cancer, primary sclerosing cholangitis, and primary biliary cholangitis but not with gallbladder polyps. While causal links have been reported, prospective longitudinal studies are required to conclude the association between H. pylori and gallbladder pathologies. Clinicians should be aware of the implications that H. pylori infection has on the management of these diseases.

show abstract

Decipher the Helicobacter pylori Protein Targeting in the Nucleus of Host Cell and their Implications in Gallbladder Cancer: An insilico approach

Cited by 16 publications

References 45 publications

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab

Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab

The footprint of gut microbiota in gallbladder cancer: a mechanistic review

The link between Helicobacter pylori infection and gallbladder and biliary tract diseases: A review

Contact Info

Product

Resources

About